SCHEDULE 13G/A: Great Point Partners and Affiliates Disclose 9.99% Stake in ProMIS Neurosciences

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly disclosed a beneficial ownership of 9.99% in ProMIS Neurosciences Inc., totaling 3,334,520 common shares.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 3,334,520 common shares of ProMIS Neurosciences Inc.
• This aggregate ownership represents 9.99% of the issuer's common shares outstanding.
• The calculation of the percentage is based on a total of 33,378,582 shares outstanding, which includes 32,689,190 common shares reported in the Issuer's Form 10-Q on November 14, 2024, plus 689,392 shares issuable upon exercise of warrants held by the reporting persons, subject to a beneficial ownership cap.
• The reporting persons hold shared voting and shared dispositive power over all 3,334,520 shares.
• The filing indicates that the securities were not acquired or held for the purpose of changing or influencing the control of ProMIS Neurosciences Inc.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It neither indicates positive nor negative operational performance, but rather a significant investment position.

Risks

• The beneficial ownership of warrants is subject to a 'Beneficial Ownership Cap' which restricts exercise if it would result in ownership exceeding 9.99% of the outstanding common shares, potentially limiting the full conversion of warrants.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding the issuer's operations or financial performance, focusing solely on beneficial ownership disclosure.

Industry Context

This filing is a standard disclosure of a significant passive investment stake in a publicly traded company, common in the financial industry for investment firms and their principals. It indicates a notable position taken by Great Point Partners in a neuroscience company, which could be interpreted as a vote of confidence in the sector or the specific company's potential.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by an investment firm and its principals may be viewed positively, signaling institutional confidence in the company. However, the passive nature of the investment (not for control) means no immediate strategic changes are implied.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, ProMIS Neurosciences Inc., Great Point Partners, Equity Stake, SEC Filing, Common Shares, Investment, Warrants